CareDx, Inc: valuation
What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.
Cash-flow value
Fewer than two of the last three years have both cash from operations and capital spending on file.
Your own DCF model
A full discounted-cash-flow model of CareDx, Inc, started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.
Open the DCF modelAgainst the industry Diagnostics and Research
Multiples of its companies with a market value at most 60 days old, times CareDx, Inc's own figures of FY2025.
| Multiple | Peers (25th / median / 75th) | CareDx, Inc | Applied to | Value (25th to 75th) | Companies |
|---|---|---|---|---|---|
| Price to sales | 2.3× / 4.8× / 8.0× | 6.8× | revenue $380 M | $874 M to $3.0 B | 36 |
| Price to book | 2.7× / 6.4× / 14.0× | 11.1× | book equity $303 M | $824 M to $4.2 B | 34 |
Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.
Against its own history
CareDx, Inc's multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.
P/E
30.3×Now above its median of 15.3×, in the top quarter of its range; range 11.5× to 30.3× over 12 months.
Price to sales
7.3×Now above its median of 3.0×, in the top quarter of its range; range 1.9× to 43.7× over 28 months.
Price to book
11.1×Now above its median of 2.9×, in the top quarter of its range; range 1.3× to 36.0× over 28 months.
as of Oct 19, 2026. Market caps: the dated values on file since 2020, and in between the SEC's fails-to-deliver closing price times the share count on the latest 10-K or 10-Q cover. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Oct 19, 2026.
The statements it starts from
USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.
| Fiscal year | Revenue | Net income | Cash from operations | Capital spending | Free cash flow | Net debt | Source |
|---|---|---|---|---|---|---|---|
| FY2025to Dec 31, 2025 | $380 M | $-21 M | $42 M | — | — | — | SEC annual report (10-K, 20-F) |
| FY2024to Dec 31, 2024 | $334 M | $53 M | $38 M | — | — | — | SEC annual report (10-K, 20-F) |
| FY2023to Dec 31, 2023 | $280 M | $-190 M | $-18 M | — | — | — | SEC annual report (10-K, 20-F) |
| FY2022to Dec 31, 2022 | $322 M | $-77 M | $-25 M | — | — | — | SEC annual report (10-K, 20-F) |
| FY2021to Dec 31, 2021 | $296 M | $-31 M | $-19 M | — | — | — | SEC annual report (10-K, 20-F) |
| FY2020to Dec 31, 2020 | $192 M | $-19 M | $33 M | — | — | $-135 M | SEC annual report (10-K, 20-F) |
Each figure as filed; the full statements with every line and its filing are on the company page. Market value $3.4 B on Oct 19, 2026.
How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.